Member Info for Kevinl1977

As RM said, data is key.
Let’s hope they find the one that opens the door to approval.

‘In addition to monitoring drug safety, the lifecycle evaluation approach enables regulators to approve drugs based on clinical evidence that is less robust, with the understanding that drugs will continue to be evaluated after approval.’
This sounds like a possibility for us. Pretty sure if we were a major pharma we would have applied already.

Conditional upon a successful phase 3 readout.
I’m not sure if you’re aware, but at this moment in time, I don’t think anyone sees it as successful readout. Hence, why in the updated RNS there was no mention of an impending EUA. That’s why I asked for the new evidence.
Have I missed something??

Doc
Good to see you posting, hope you’re okay.
One thing I never considered pre-P3, was how SOC would differ across the different countries and how that might compromise the trial.
Let’s hope statistical positives can be raised in the deep dive.
ATB

Sent to Brooke.
I also raised the very small attention to detail error, manifesto.
Regards

Cheers manifesto.
Tony - nice to see you’re still around, but watching from afar.
ATB

Manifesto
Many thanks, drrrr.
Had a dumb moment.

I sent an email through the managed access programme, via Synairgens website. This directs you through to Clinigen.
I asked about the possibility of combining data, etc and if an EUA was still their hope.
The response I received was, ‘ I am not confident you are in contact with the correct department. To enable me to assist you further, please advise the company you are contacting us from and the department/contact you are needing assistance from. within Clinigen’.
Anyone else had this, as I thought Clinigen were handling emails?
Has anyone got Brooke Clarke’s email address as I can’t locate it on the website?
Regards

It finished 24.62.

Hear hear

Cheers Tommy.
Yes, different SOC across the many countries may have been just one reason why endpoints weren’t met.
Not read it all yet, but great post.
ATB

Just saying.

Manifesto
Yes, that may hopefully be the case.
I have asked the same question from our Head of Comms, but have received nothing.
I thought I had missed something!
ATB

Tommy
Can you show me where the company have said that, post Sprinter readout?

Will Synairgen apply for EUA, if data is combined and also if it unearths some key positives from the deep dive analysis? Is this a direct question for our Head of Comms?
Does she have a part time role now, because I would love to know what her job description entails and how she fills her time?

Thanks folks for this update.
I’m sure RM is aware of this, then again :)

‘And before you ask - yes I am an investor in this share.’
So, you’re not invested, hence my previous comment.

Elsol
£2.50ish at this point would be very nice.
Yes, pls.
:)

Thankyou.
ATB to you also!
Let’s hope we have a few months of positivity to look forward to.
Peace and prosperity to all, including SNG LTH’s.

Yes, agreed manifesto.
Another moby.